Yesterday, at the American College of Gastroenterology’s (ACG) annual conference, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) presented long-term safety data for its pipeline drug plecanatide …
Canaccord analyst John Newman provides positive perspective on Lipocine Inc (NASDAQ:LPCN), encouraged by the biotech firm’s lead oral testosterone product, LPCN-1111, a drug …
Analysts offer insights into a volatile biotech-verse amid Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares dipping on news of a program termination and Aurinia Pharmaceuticals (NASDAQ:AUPH) soaring on …
In a research report released Tuesday, Canaccord analyst John Newman reiterated a Buy rating on shares of Palatin Technologies, Inc. (NYSEMKT:PTN) with a $6.
Aerie Pharmaceuticals Inc’s (NASDAQ:AERI) pipeline drug Roclatan, a novel once-daily, quadruple-action eye drop being tested for its ability to lower intraocular pressure (IOP) …
Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced that its collaboration partner Celgene Corporation (NASDAQ:CELG) intends to file for an NDA for its AML-treating drug AG-221 …
Canaccord reiterates Buy for Cerulean, but slashes price target from $15 to $6 following clinical setback
In a research report published Wednesday, Canaccord analyst John Newman reiterated a Buy rating on shares of Medivation Inc (NASDAQ:MDVN) with a price target …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its second-quarter earnings results today, with U.S.
Shares of Mast Therapeutics Inc (NYSEMKT:MSTX) are down 15% on Tuesday after the company disclosed that it now expects top-line results from the Phase 3 EPIC …
